Loss of PPM1A expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-β/Smad signaling pathway

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5700-5711

  Geng, Jiang ^a   Fan, Jie ^b   Ouyang, Qi ^b   Zhang, Xiaopeng ^a   Zhang, Xiaolong ^a   Yu, Juan ^b   Xu, Zude ^b   Li, Qianyu ^a   Yao, Xudong ^a   Liu, Xiuping ^b   Zheng, Junhua ^a  

^a TONGJI UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

EMT; Muscle invasive; PPM1A; TGF signaling; Urinary bladder cancer

Indexed keywords

PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PHOSPHATASE MAGNESIUM ION MANGANESE ION DEPENDENT 1A; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; PROTEIN PHOSPHATASE 2C; SMAD2 PROTEIN; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN; SMAD3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL MOTILITY; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PROTEIN DEPHOSPHORYLATION; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TUMOR INVASION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLADDER TUMOR; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PHOSPHOPROTEIN PHOSPHATASES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; URINARY BLADDER NEOPLASMS;

EID: 84906218131     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2144     Document Type: Article

References (48)

1. Siegel R, Naishadham D and Jemal A Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30.
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J and Roupret M EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. Eur Urol. 2013.
3. Kaufman DS, Shipley WU and Feldman AS. Bladder cancer Lancet 2009; 374(9685):239-249.
4. Parekh DJ, Bochner BH and Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol. 2006; 24(35):5519-5527.
5. Malkowicz SB, van Poppel H, Mickisch G, Pansadoro V, Thuroff J, Soloway MS, Chang S, Benson M and Fukui I Muscle-invasive urothelial carcinoma of the bladder Urology. 2007; 69(1 Suppl):3-16.
6. Akhurst RJ and Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol. 2001; 11(11):S44-51.
7. Derynck R, Akhurst RJ and Balmain A.TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001; 29(2):117-129.
8. Wei H, Kamat AM, Aldousari S, Ye Y, Huang M, Dinney CP and Wu X. Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. PLoS One 2012; 7(12):e51758.
9. Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, Lerner SP and Slawin KM. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma Cancer 2001; 92(12):2985-2992.
10. Pardali K and Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochimica et biophysica acta. 2007; 1775(1):21-62.
11. Akhurst RJ and Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends in cell biology 2001; 11(11):S44-51.
12. Wakefield LM and Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis Current opinion in genetics & development. 2002; 12(1):22-29.
13. Das AK, Helps NR, Cohen PT and Barford D. Crystal structure of the protein serine/threonine phosphatase 2C at 2.0 A resolution. The EMBO journal 1996;15(24):6798-6809.
14. Bourgeois B, Gilquin B, Tellier-Lebegue C, Ostlund C, Wu W, Perez J, El Hage P, Lallemand F, Worman HJ and Zinn-Justin S. Inhibition of TGF-beta signaling at the nuclear envelope: characterization of interactions between MAN1, Smad2 and Smad3, and PPM1A Sci Signal. 2013; 6(280):ra49.
15. Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, Hu M, Davis CM, Wang J, Brunicardi FC, Shi Y, Chen YG, Meng A and Feng XH. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling Cell. 2006; 125(5):915-928.
16. Zhang B, Zhou Z, Lin H, Lv X, Fu J, Lin P, Zhu C and Wang H. Protein phosphatase 1A (PPM1A) is involved in human cytotrophoblast cell invasion and migration Histochem Cell Biol. 2009; 132(2):169-179.
17. Lammers T, Peschke P, Ehemann V, Debus J, Slobodin B, Lavi S and Huber P. Role of PP2Calpha in cell growth, in radio-and chemosensitivity, and in tumorigenicity. Mol Cancer. 2007; 6:65.
18. Wu SK, Wang BJ, Yang Y, Feng XH, Zhao XP and Yang DL. Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues. World J Gastroenterol. 2007; 13(34):4554-4559.
19. Jungert K, Buck A, von Wichert G, Adler G, Konig A, Buchholz M, Gress TM and Ellenrieder V. Sp1 is required for transforming growth factor-beta-induced mesenchymal transition and migration in pancreatic cancer cells. Cancer research. 2007; 67(4):1563-1570.
20. Mitra AP, Datar RH and Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin 2006; 24(35):5552-5564.
21. Goebell PJ and Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol. 2010; 28(4):409-428.
22. Geng J, Fan J, Wang P, Fang ZJ, Xia GW, Jiang HW, Chen G and Ding Q. REG1A predicts recurrence in stage Ta/T1 bladder cancer European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2009; 35(8):852-857.
23. Goto N, Hiyoshi H, Ito I, Iida K, Nakajima Y, Nagasawa K and Yanagisawa J. Identification of a Novel Compound That Suppresses Breast Cancer Invasiveness by Inhibiting Transforming Growth Factor-beta Signaling via Estrogen Receptor alpha. J Cancer. 2014; 5(5):336-343.
24. Dituri F, Mazzocca A, Peidro FJ, Papappicco P, Fabregat I, De Santis F, Paradiso A, Sabba C and Giannelli G. Differential Inhibition of the TGF-beta Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-beta Receptor Type II. PLoS One. 2013; 8(6):e67109.
25. Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A and Guise TA. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 2011; 71(1):175-184.
26. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, Miwa A and Hirakawa K. Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice. Cancer Sci. 2010; 101(8):1846-1852.
27. Kim JH, Shariat SF, Kim IY, Menesses-Diaz A, Tokunaga H, Wheeler TM and Lerner SP Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92(6):1475-1483.
28. Eder IE, Stenzl A, Hobisch A, Cronauer MV, Bartsch G and Klocker H. Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma. J Urol. 1996; 156(3):953-957.
29. Al-Azayzih A, Gao F, Goc A and Somanath PR TGFbeta1 induces apoptosis in invasive prostate cancer and bladder cancer cells via Akt-independent, p38 MAPK and JNK/SAPK-mediated activation of caspases. Biochem Biophys Res Commun. 2012; 427(1):165-170.
30. Lin X, Chen Y, Meng A and Feng X. Termination of TGF-beta superfamily signaling through SMAD dephosphorylation-a functional genomic view. J Genet Genomics. 2007; 34(1):1-9.
31. Geng J, Fan J, Wang P, Fang ZJ, Xia GW, Jiang HW, Chen G and Ding Q. REG1A predicts recurrence in stage Ta/T1 bladder cancer. Eur J Surg Oncol. 2009; 35(8):852-857.
32. Takekawa M, Maeda T and Saito H. Protein phosphatase 2Calpha inhibits the human stress-responsive p38 and JNK MAPK pathways. Embo J. 1998; 17(16):4744-4752.
33. Wang Y, Dow EC, Liang YY, Ramakrishnan R, Liu H, Sung TL, Lin X and Rice AP. Phosphatase PPM1A regulates phosphorylation of Thr-186 in the Cdk9 T-loop. J Biol Chem. 2008; 283(48):33578-33584.
34. Yoshizaki T, Maegawa H, Egawa K, Ugi S, Nishio Y, Imamura T, Kobayashi T, Tamura S, Olefsky JM and Kashiwagi A. Protein phosphatase-2C alpha as a positive regulator of insulin sensitivity through direct activation of phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J Biol Chem. 2004; 279(21):22715-22726.
35. Lu X, An H, Jin R, Zou M, Guo Y, Su PF, Liu D, Shyr Y and Yarbrough WG. PPM1A is a RelA phosphatase with tumor suppressor-like activity. Oncogene. 2014; 33(22):2918-2927.
36. Pierreux CE, Nicolas FJ and Hill CS. Transforming growth factor beta-independent shuttling of Smad4 between the cytoplasm and nucleus. Mol Cell Biol. 2000; 20(23):9041-9054.
37. Dai F, Duan X, Liang YY, Lin X and Feng XH. Coupling of dephosphorylation and nuclear export of Smads in TGF-beta signaling. Methods Mol Biol. 2010; 647:125-137.
38. Inman GJ, Nicolas FJ and Hill CS. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol Cell. 2002; 10(2):283-294.
39. Zhang SS, Wan XY, Zhou CY, Lu WG and Xie X. [Expression and significance of LMP2 and PPM1A in gestational trophoblastic disease]. Zhonghua Fu Chan Ke Za Zhi. 2011; 46(7):510-515.
40. Lee JM, Dedhar S, Kalluri R and Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006; 172(7):973-981.
41. Pardali K and Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta. 2007; 1775(1):21-62.
42. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6):442-454.
43. Peinado H, Portillo F and Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004; 48(5-6):365-375.
44. Yang Y, Pan X, Lei W, Wang J, Shi J, Li F and Song J. Regulation of transforming growth factor-beta 1-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and signal transducers and activators of transcription 3. Cancer Res. 2006; 66(17):8617-8624.
45. Cohen M, Meisser A, Haenggeli L and Bischof P. Involvement of MAPK pathway in TNF-alpha-induced MMP-9 expression in human trophoblastic cells. Mol Hum Reprod. 2006; 12(4):225-232.
46. Cohen M, Wuillemin C, Irion O and Bischof P. Regulation of MMP-9 by p53 in first trimester cytotrophoblastic cells. Hum Reprod. 2008; 23(10):2273-2281.
47. Shen YH, Song GX, Liu YQ, Sun W, Zhou LJ, Liu HL, Yang R, Sheng YH, Qian LM and Kong XQ. Silencing of FABP3 promotes apoptosis and induces mitochondrion impairment in embryonic carcinoma cells. Journal of bioenergetics and biomembranes. 2012; 44(3):317-323.
48. Azuma H, Ehata S, Miyazaki H, Watabe T, Maruyama O, Imamura T, Sakamoto T, Kiyama S, Kiyama Y, Ubai T, Inamoto T, Takahara S, Itoh Y, Otsuki Y, Katsuoka Y and Miyazono K, et al. Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. Journal of the National Cancer Institute. 2005; 97(23):1734-1746.